01—Abstract
Summary
Summary of the 10-K filed March 3, 2011. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. (DXCM) presented its 2010 Form 10-K filing, detailing its progress as a medical device company focused on continuous glucose monitoring (CGM) systems.
The company's primary product, the SEVEN PLUS system, is designed for ambulatory use by individuals with diabetes and saw increased sales volume and average selling prices in 2010 compared to 2009. Despite revenue growth, DexCom continued to incur significant operating losses, consistent with its early commercialization stage, with a reported net loss of $55.17 milliona for the year. The company is actively investing in research and development for next-generation products and exploring the in-hospital market with its GlucoClear system.
Key financial and operational highlights include a substantial increase in product revenue to $40.2 millionb, driven by higher sales of the SEVEN PLUS system. However, the company's operating expenses, particularly in selling, general, and administrative functions, also rose significantly. DexCom secured additional funding through follow-on public offerings, raising approximately $66 million in 2010 to support its ongoing commercialization and development efforts.
The company is also navigating significant legal challenges, including a patent infringement lawsuit with Abbott Diabetes Care, which poses a notable risk. Despite the ongoing losses, DexCom is positioning itself for future growth by expanding its sales force and advancing its technology platform.
02—Key points
Key Highlights
- Product revenue increased by over 120% from $18.0 million in 2009 to $40.2 million in 2010, driven by higher sales volume and average selling prices of the SEVEN PLUS system.
- The company incurred a net loss of $55.17 million in 2010, reflecting significant ongoing investment in research and development ($23.2 million) and selling, general, and administrative expenses ($40.5 million) to support commercialization.
- DexCom raised approximately $66 million in net proceeds from two follow-on public offerings in 2010, bolstering its cash position to $47.1 million (excluding restricted cash) as of year-end.
- Significant legal proceedings are ongoing with Abbott Diabetes Care regarding patent infringement, with potential implications for DexCom's product portfolio and business operations.
- The company is pursuing broader market penetration by expanding its direct sales force and exploring partnerships for its continuous glucose monitoring technology.
- DexCom's GlucoClear system, designed for in-hospital use, received CE Mark approval but generated minimal revenue, with continued efforts to gain FDA clearance.
- The company faces challenges related to third-party reimbursement, with most payors having restrictive coverage policies, impacting product adoption and revenue potential.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2010, Dexcom Inc lost $1.14.
- Revenue$48.6M100.0%
- Cost of revenue−$30.2M62.1%
- Gross profit$18.4M37.9%
- Operating costs−$63.7M131.1%
- Operating income−$45.3M93.2%
- Interest, other & tax−$9.9M20.4%
- Net income−$55.2M113.6%
04—Financials
Financial Highlights
Figures from 10-KFY2010filed March 3, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $48.60M$29.69M | +63.7% |
| Cost of Revenue | $30.20M$26.03M | +16.0% |
| Gross Profit | $18.40M$3.66M | +402.6% |
| R&D Expenses | $23.20M$14.29M | +62.3% |
| SG&A Expenses | $40.50M$35.20M | +15.1% |
| Operating Expenses | $63.70M$49.49M | +28.7% |
| Operating Income | -$45.30M-$45.83M | +1.2% |
| Interest Expense | $1.50M$8.04M | −81.4% |
| Net Income | -$55.20M-$53.52M | −3.1% |
| EPS (Basic) | $-0.24$-0.30 | +19.8% |
| Shares Outstanding (Basic) | 227.60M— | — |
05—Questions
Frequently Asked Questions
What is DexCom's primary product and its market performance in 2010?
DexCom's primary product is the SEVEN PLUS, a continuous glucose monitoring system for people with diabetes. In 2010, product revenue significantly increased to $40.2 million from $18.0 million in 2009, driven by higher sales volumes and increased average selling prices.
Is DexCom profitable, and what is its financial outlook?
No, DexCom is not yet profitable. The company incurred a net loss of $55.17 million in 2010, which is consistent with its strategy of investing heavily in research and development and sales and marketing for commercialization. The company anticipates continuing to incur significant operating losses for the foreseeable future.
What are the major risks facing DexCom, as highlighted in the filing?
Key risks include the company's limited operating history and the potential for its products to not achieve widespread market acceptance. Other significant risks involve ongoing patent litigation with Abbott Diabetes Care, dependence on third-party payor reimbursement, the need for continued financing, the challenges of scaling manufacturing, and regulatory compliance.
How is DexCom funding its operations and growth?
DexCom is primarily funded through equity financings. In 2010, the company completed two follow-on public offerings, raising approximately $66 million in net proceeds. These funds are used to support commercialization, research and development, and expansion of its infrastructure.
06—Continue